CREBBP mutations in relapsed acute lymphoblastic leukaemia.

PubWeight™: 3.72‹?› | Rank: Top 1%

🔗 View Article (PMC 3076610)

Published in Nature on March 10, 2011

Authors

Charles G Mullighan1, Jinghui Zhang, Lawryn H Kasper, Stephanie Lerach, Debbie Payne-Turner, Letha A Phillips, Sue L Heatley, Linda Holmfeldt, J Racquel Collins-Underwood, Jing Ma, Kenneth H Buetow, Ching-Hon Pui, Sharyn D Baker, Paul K Brindle, James R Downing

Author Affiliations

1: Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

Associated clinical trials:

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111

Articles citing this

(truncated to the top 100)

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51

Acute lymphoblastic leukaemia. Lancet (2013) 3.44

The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40

Interplay between the cancer genome and epigenome. Cell (2013) 3.05

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82

Wnt signaling in cancer. Cold Spring Harb Perspect Biol (2012) 2.75

Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50

The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49

Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41

Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet (2011) 2.32

Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell (2012) 2.15

Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res (2012) 2.01

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood (2014) 2.00

The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun (2014) 1.90

The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90

Harnessing of the nucleosome-remodeling-deacetylase complex controls lymphocyte development and prevents leukemogenesis. Nat Immunol (2011) 1.89

The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83

TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol (2012) 1.78

Challenging issues in pediatric oncology. Nat Rev Clin Oncol (2011) 1.56

Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun (2015) 1.49

Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature (2014) 1.47

Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood (2013) 1.46

Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest (2012) 1.38

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol (2015) 1.37

Chromium in drinking water: sources, metabolism, and cancer risks. Chem Res Toxicol (2011) 1.34

Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun (2014) 1.33

Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia (2012) 1.22

Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene (2013) 1.20

Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A (2012) 1.19

Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.19

Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood (2015) 1.19

CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia (2012) 1.18

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood (2014) 1.16

Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia (2013) 1.14

Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatin. Genes Dev (2011) 1.12

Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease. Epigenomics (2012) 1.10

Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet (2016) 1.07

Epigenetic control of immunity. Cold Spring Harb Perspect Biol (2014) 1.05

Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A (2015) 1.03

Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol (2013) 1.02

Protein lysine acetylation by p300/CBP. Chem Rev (2015) 1.02

De novo mutations in the genome organizer CTCF cause intellectual disability. Am J Hum Genet (2013) 1.01

Childhood B-acute lymphoblastic leukemia: a genetic update. Exp Hematol Oncol (2014) 1.01

[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. J Med Chem (2013) 1.01

Epigenetics and B-cell lymphoma. Curr Opin Hematol (2011) 0.98

Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98

Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am (2015) 0.97

Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol (2014) 0.97

Genomic occupancy of the transcriptional co-activators p300 and CBP. Transcription (2012) 0.97

Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica (2015) 0.96

KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. Leukemia (2015) 0.96

Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol (2014) 0.96

Genomic profiling of B-progenitor acute lymphoblastic leukemia. Best Pract Res Clin Haematol (2011) 0.95

Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer (2015) 0.95

Is histone acetylation the most important physiological function for CBP and p300? Aging (Albany NY) (2012) 0.95

Mining functional subgraphs from cancer protein-protein interaction networks. BMC Syst Biol (2012) 0.94

Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. Curr Pharm Des (2013) 0.93

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. Front Oncol (2014) 0.93

Targeting the WNT Signaling Pathway in Cancer Therapeutics. Oncologist (2015) 0.92

Epigenetic changes: a common theme in acute myelogenous leukemogenesis. J Hematol Oncol (2013) 0.92

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget (2015) 0.92

PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. Blood (2015) 0.91

Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J Biol Chem (2014) 0.91

CREB and leukemogenesis. Crit Rev Oncog (2011) 0.91

Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. Oncotarget (2016) 0.91

A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther (2013) 0.91

The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies. Lab Invest (2015) 0.91

KATs in cancer: functions and therapies. Oncogene (2015) 0.89

Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments. Curr Hematol Malig Rep (2012) 0.89

JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia (2016) 0.89

Chromatin-regulating proteins as targets for cancer therapy. J Radiat Res (2014) 0.88

CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy. Cancer Res (2014) 0.88

Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis (2014) 0.88

Understanding resistance to combination chemotherapy. Drug Resist Updat (2012) 0.88

Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome. Nat Commun (2015) 0.88

Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. PLoS Genet (2015) 0.87

Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells. Blood (2011) 0.87

Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. Haematologica (2014) 0.87

Polycomb genes, miRNA, and their deregulation in B-cell malignancies. Blood (2015) 0.87

Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis. Cell Death Differ (2012) 0.87

Targeting Transcription Factors in Cancer. Trends Cancer (2015) 0.86

Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia. EBioMedicine (2016) 0.86

Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes. Nat Commun (2015) 0.86

Targeting mTOR for the treatment of B cell malignancies. Br J Clin Pharmacol (2016) 0.85

The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. J Pediatr Hematol Oncol (2014) 0.85

The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene (2015) 0.85

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife (2016) 0.84

Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis. Cancer Res (2012) 0.84

Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leuk Res Rep (2012) 0.83

Epigenetics in the hematologic malignancies. Haematologica (2014) 0.83

The HTLV-1-encoded protein HBZ directly inhibits the acetyl transferase activity of p300/CBP. Nucleic Acids Res (2012) 0.83

Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res (2012) 0.83

Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood (2013) 0.83

Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2016) 0.82

Promoter hypermethylation-induced transcriptional down-regulation of the gene MYCT1 in laryngeal squamous cell carcinoma. BMC Cancer (2012) 0.82

Epigenetic modifications in pediatric acute lymphoblastic leukemia. Front Pediatr (2014) 0.82

Articles cited by this

Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res (1998) 106.16

Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res (1998) 96.63

dbSNP: the NCBI database of genetic variation. Nucleic Acids Res (2001) 76.97

Consed: a graphical tool for sequence finishing. Genome Res (1998) 59.36

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68

Announcing the worldwide Protein Data Bank. Nat Struct Biol (2003) 17.06

Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01

A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res (1991) 13.54

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35

CBP/p300 in cell growth, transformation, and development. Genes Dev (2000) 10.76

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12

SNPdetector: a software tool for sensitive and accurate SNP detection. PLoS Comput Biol (2005) 10.04

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25

Acute lymphoblastic leukaemia. Lancet (2008) 8.54

Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20

CREB-binding protein and p300 in transcriptional regulation. J Biol Chem (2001) 4.67

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35

The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res (2004) 3.30

Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev (2000) 3.24

p300/CBP and cancer. Oncogene (2004) 3.13

High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia (2007) 2.85

The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature (2008) 2.83

CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood (2000) 2.57

Tumors in Rubinstein-Taybi syndrome. Am J Med Genet (1995) 2.56

Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood (1999) 2.48

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia (2010) 2.17

Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. Mol Cell Biol (2006) 2.00

Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 1.92

Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell (2004) 1.80

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood (2008) 1.79

HapScope: a software system for automated and visual analysis of functionally annotated haplotypes. Nucleic Acids Res (2002) 1.60

CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. EMBO J (2010) 1.55

Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol (2008) 1.50

Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity. Nucleic Acids Res (2001) 1.40

Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res (2005) 1.34

Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). Genome Res (2007) 1.22

Genotype-phenotype correlations in Rubinstein-Taybi syndrome. Am J Med Genet A (2008) 1.18

Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias. Cancer Lett (2004) 1.09

Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood (1994) 1.03

HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol (2007) 0.98

Articles by these authors

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23

Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A (2002) 20.48

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68

PID: the Pathway Interaction Database. Nucleic Acids Res (2008) 12.92

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12

SNPdetector: a software tool for sensitive and accurate SNP detection. PLoS Comput Biol (2005) 10.04

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Large-scale sequence analysis of avian influenza isolates. Science (2006) 9.87

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25

The BioPAX community standard for pathway data sharing. Nat Biotechnol (2010) 9.19

Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95

Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61

Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32

caCORE: a common infrastructure for cancer informatics. Bioinformatics (2003) 7.07

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64

Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06

Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86

Global transcription in pluripotent embryonic stem cells. Cell Stem Cell (2008) 5.81

Allelic variation in gene expression is common in the human genome. Genome Res (2003) 5.50

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20

Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci (2007) 5.02

A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02

JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93

Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2012) 4.92

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89

Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88

Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82

Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54

An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A (2002) 4.45

Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35

The tumor lysis syndrome. N Engl J Med (2011) 4.29

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21

Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16

Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA (2004) 4.04

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood (2010) 4.00

Long-range heterogeneity at the 3' ends of human mRNAs. Genome Res (2002) 3.91